|
2024 Journal Article Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyAzad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6 |
|
2024 Journal Article The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohortTariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Pelecanos, Anita, Gan, Chun Loo, Goh, Jeffrey C., Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2024). The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort. European Urology Focus, 10 (5), 770-778. doi: 10.1016/j.euf.2023.12.004 |
|
2024 Conference Publication A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)Azad, A.A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A.J., Guminski, A., Francis, R.J., Saghebi, J., Dhiantravan, N., Joshua, A., Emmett, L., Murphy, D., Hsiao, E., Lee, S.T., Pattison, D.A., Nadebaum, D., Kirkwood, I.D. and Hofman, M.S. (2024). A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.2309 |
|
2024 Journal Article Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancerButeau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2024). Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. European Urology Oncology, 7 (3), 544-552. doi: 10.1016/j.euo.2023.11.008 |
|
2024 Journal Article [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9 |
|
2024 Book Chapter Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignanciesAlexander, Erik K., Haymart, Megan R., Pattison, David A., Wirth, Lori J. and Zeiger, Martha A. (2024). Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies. Williams textbook of endocrinology. (pp. 430.e14-470.e14) edited by Shlomo Melmed, Richard J. Auchus, Allison B. Goldfine, Clifford J. Rosen and Peter A. Kopp. Amsterdam, Netherlands: Elsevier. doi: 10.1016/B978-0-323-93230-1.00012-9 |
|
2024 Journal Article First-in-human212Pb-PSMA–targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancerGriffiths, Matthew R., Pattison, David A., Latter, Melissa, Kuan, Kevin, Taylor, Stephen, Tieu, William, Kryza, Thomas, Meyrick, Danielle, Lee, Boon Quan, Hansen, Aaron, Rose, Stephen E. and Puttick, Simon G. (2024). First-in-human212Pb-PSMA–targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 65 (4), 664-664. doi: 10.2967/jnumed.123.267189 |
|
2024 Journal Article Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6 |
|
2024 Book Chapter Role of Functional Imaging in NENsChan, David L., Pattison, David A. and Kong, Grace (2024). Role of Functional Imaging in NENs. Endocrinology. (pp. 1-24) Cham, Switzerland: Springer. doi: 10.1007/978-3-030-67823-4_8-1 |
|
2023 Journal Article Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRIArnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul and Ramsay, Stuart (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology, 30 (6), 2676-2691. doi: 10.1007/s12350-023-03345-w |
|
2023 Journal Article Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma managementPathmanathan, Shivanshan, Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C., Gan, Chun Loo and Roberts, Matthew J. (2023). Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management. European Journal of Nuclear Medicine and Molecular Imaging, 51 (1), 295-303. doi: 10.1007/s00259-023-06380-4 |
|
2023 Journal Article Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06Barry, Nathaniel, Francis, Roslyn J., Ebert, Martin A., Koh, Eng-Siew, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Kendrick, Jake, Gan, Hui K., Lee, Sze T., Lau, Eddie, Moffat, Bradford A., Fitt, Greg, Moore, Alisha, Thomas, Paul, Pattison, David A., Akhurst, Tim, Alipour, Ramin, Thomas, Elizabeth L., Hsiao, Edward, Schembri, Geoffrey P., Lin, Peter, Ly, Tam, Yap, June, Kirkwood, Ian, Vallat, Wilson, Khan, Shahroz, Krishna, Dayanethee, Ngai, Stanley, Yu, Chris ... Scott, Andrew M. (2023). Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06. European Journal of Nuclear Medicine and Molecular Imaging, 50 (13), 3970-3981. doi: 10.1007/s00259-023-06371-5 |
|
2023 Conference Publication Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND TrialRoberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Journal Article Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)Li, Minmin, Chan, David L., Tapia Rico, Gonzalo, Cehic, Gabrielle, Lawrence, Ben, Wyld, David, Pattison, David A., Kong, Grace, Hicks, Rodney, Michael, Michael, Kiberu, Andrew Ddembe, Lim, Jennifer, Clifton-Bligh, Roderick, Tsang, Venessa, Roach, Paul J., Leyden, John, Diakos, Connie I., Price, Timothy J. and Pavlakis, Nick (2023). Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology, 113 (3), 281-288. doi: 10.1159/000526848 |
|
2023 Conference Publication Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Weickhardt, Andrew James, Lee, Sze Ting, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D. and Emmett, Louise (2023). Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
|
2022 Journal Article Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic dietBennett, O. A., Ramsay, S. C., Malacova, E., Bourgeat, P., Goodman, S. J., Dunn, C. J., Robinson, B. M., Lee, K. and Pattison, D. A. (2022). Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet. European Journal of Hybrid Imaging, 6 (1) 29, 1-16. doi: 10.1186/s41824-022-00150-5 |
|
2022 Journal Article PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialButeau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Banks, Patricia, Beaulieu, Alexis, Chua, Wei, Dhiantravan, Nattakorn, Ford, Kate, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J ... for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23 (11), 1389-1397. doi: 10.1016/S1470-2045(22)00605-2 |
|
2022 Journal Article 99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging-Histopathologic CorrelationWang, Ray, Better, Nathan, Sivaratnam, Dinesh, Westcott, James, Forehan, Simon, Christie, Michael, Pattison, David A. and Fourlanos, Spiros (2022). 99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging-Histopathologic Correlation. Clinical Nuclear Medicine, 47 (9), E582-E584. doi: 10.1097/RLU.0000000000004332 |
|
2022 Journal Article Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)Tariq, Arsalan, McGeorge, Stephen, Pearce, Adam, Rhee, Handoo, Wood, Simon, Kyle, Samuel, Marsh, Philip, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Westera, Jurjen, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2022). Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology: Seminars and Original Investigations, 40 (6), 276.e1-276.e9. doi: 10.1016/j.urolonc.2022.03.007 |
